SARS-CoV-2 Antigen Rapid Qualitative Test Type A

Carcinoembryonic antigen (CEA) is a protein normally found in very low levels in the blood of adults. The CEA blood level may be increased in certain types of cancer and non-cancerous (benign) conditions. A CEA test is most commonly used for colorectal cancer.

The MPV IgG/IgM Rapid Test is a lateral flow chromatographic immunoassay for the qualitative detection and differentiation of IgM and IgG antibodies to Monkeypox Virus (MPV) in human serum, plasma, venous whole blood, or fingertip blood. It is intended for use as an aid in identifying individuals with an adaptive immune response to MPV, indicating recent or prior infection. At this time, it is unknown how long antibodies persist following infection and if the presence of antibodies confers protective immunity. The MPV IgG/IgM Rapid Test should not be used to diagnose acute MPV infection. For professional in vitro diagnostic use only.

COVID-19 Ag & Flu A/B Combo Self Test is a colloidal gold immunochromatography intended for the in vitro rapid, simultaneous qualitative detection and differentiation of N protein from SARS-CoV-2, influenza A and influenza B directly from nasal swab specimens obtained from individuals, who are suspected of COVID-19, influenza A or influenza B infection. Results are for the simultaneous identification of N protein of SARS-CoV-2, influenza A and influenza B.

Cardiac markers are used in the diagnosis and risk stratification of patients with chest pain, suspected Acute Coronary Syndrome(ACS) and Heart Failure(HF), etc.

The incubation chamber is an auxiliary device for Biotime’s fluorescence immunoassay analyzer. The reaction temperature and time is critical for test results. The incubation chamber provides an optimized environment as well as automatic timers for test reactions to improve the reliability of test results.

Progesterone(PROG) is produced by the corpus luteum or in females, the male progesterone level is very low and mainly produced by adrenal cortex. Biotime PROG test is used for determining ovulation, monitoring progesterone therapy and evaluating early pregnancy status.

The ALL NEW FLI-100 Analyser represents an elevated standard at Biotime, in pursuing simplicity, quality assurance, and data security for healthcare organizations. Designed for quantitative in vitro assay determinations, the Biotime FLI-100 analyser was purposefully built to support immunoassay analysis for a broad range of applications – from biomarker work to infectious disease testing. The analyser’s immunofluorescence technology yields high sensitivity, reliable, and reproducible results for convenient point-of-care diagnostic testing on one device with a small footprint.